Clinical trials: Depressive, Symptoms Depressive Disorder, Depression
Major Depressive Disorder, Treatment Resistant Depression
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an…
- Trial name
- RUBY (NCT00789854)
- Testing
- Quetiapine XR, Lithium carbonate, SSRI/Venlafaxine
- Where
- 106 sites in Australia, Austria and 11 more
- Volunteers
- 688 people
- Sponsor
- AstraZeneca
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in…
- Trial name
- NCT00250627
- Testing
- Saredutant succinate (SR48968C)
- Where
- 8 sites in Canada, Chile and 6 more
- Volunteers
- 465 people
- Sponsor
- Sanofi
Depression / Major Depressive Disorder
Biomarkers and Pharmacogenomics for Precision Depression Therapy
Background: The clinical management of major depressive disorder (MDD) is hampered by the lack of objective biomarkers and high inter-individual variability in drug response, with conventional antidepressants achieving only a 50%…
- Trial name
- NCT07738497
- Testing
- Pharmacogenomic Testing, Antidepressant Agents
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Smoking
Behavioural Activation Treatment for Smoking Cessation and Depressive Symptomatology: a Randomized Controlled Trial
The number of people who smoke, have concurrent depression and that seek treatment for smoking cessation has increased in recent years. This implies the need to design intensive and specific interventions that target this issue.
- Trial name
- NCT02844595
- Testing
- Standard cognitive-behavioural smoking cessation treatment, Standard cognitive-behavioural smoking cessation treatment and behavioural activation
- Where
- Spain
- Volunteers
- 275 people
- Sponsor
- University of Santiago de Compostela
Depressive Disorder, Major, Suicidal
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in…
- Trial name
- NCT04669665
- Testing
- SLS-002, Standard of care, Intranasal device
- Where
- 21 sites in United States
- Volunteers
- 164 people
- Sponsor
- Seelos Therapeutics, Inc.
Adjunctive Treatment of Major Depressive Disorder
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major Depressive Disorder (MDD) participants currently treated with antidepressant therapy.
- Trial name
- NCT04103892
- Testing
- CLE-100
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 146 people
- Sponsor
- Clexio Biosciences Ltd.
Depression, Depressive Disorder
Behavioral Activation Teletherapy to Increase Physical Activity
This is a pilot study of acceptability, feasibility, and preliminary efficacy of a brief, 10-session Behavioral Activation intervention delivered via teletherapy to increase physical activity and treat depressive symptoms.
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Episode
- Trial name
- BAT (NCT04990401)
- Testing
- Behavioral Activation Teletherapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Disorder, Major Depressive Disorder
Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms
The purpose of this study is to advance a non-pharmacologic suicide preventive intervention with wide dissemination potential as an innovative high-yield solution to reduce suicide rates.
- Conditions
- Bipolar Disorder, Major Depressive Disorder, Mood Disorders, Suicide
- Trial name
- NCT05317481
- Testing
- BE-SMART-DR, psychoeducational control comparator condition (CC)
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Yale University
Major Depressive Disorder (MDD)
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.
- Trial name
- NCT00448292
- Testing
- PRX-00023
- Where
- 21 sites in United States
- Volunteers
- 330 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Depression
The Effects of taVNS on Motivation in MDD With Anhedonia
Study of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) intervention to improve the reward motivation and response inhibition of major depression disorder and its brain network mechanism.
- Trial name
- NCT06026904
- Testing
- transcutaneous auricular vagus nerve stimulation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Medical University
Depressive Disorder, Depression
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Pyxis (NCT01360645)
- Testing
- OPC-34712 + ADT
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 826 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatment Resistant Depression
Minocycline as Adjunctive Treatment for Treatment Resistant Depression
Major depressive disorder (MDD) is a leading cause of disability worldwide. Up to 50% of patients experience treatment resistant depression (TRD), which accounts for a vast majority of disease burden.
- Trial name
- MINDEP2 (NCT03947827)
- Testing
- Minocycline
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- Centre for Addiction and Mental Health
Depression
Risperidone and Suicidality in Major Depressive Disorder
The purpose of this trial is to investigate the efficacy of risperidone as an adjunct to an antidepressant treatment in the acute management of suicidality during an episode of major depressive disorder.
- Trial name
- NCT00167154
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Depressive Symptoms, Anxiety
Evaluating an Online Wellness Intervention for Indian College Students
We are evaluating the effects of an online single-session mental health intervention (the Common Elements Toolbox; COMET). To evaluate COMET, we are conducting a randomized controlled trial with Indian college students.
- Conditions
- Depressive Symptoms, Anxiety, Happiness
- Trial name
- NCT04592588
- Testing
- Common Elements Toolbox, Wait-list control
- Where
- 2 sites in India
- Volunteers
- 513 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Depressive Symptoms, Inflammation
Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention
Cardiovascular disease and depression are some of the most costly illnesses to society, and caring for a loved-one with Alzheimer's disease has been associated with increased risk for both depression and cardiovascular disease.
- Trial name
- NCT01802554
- Testing
- Pleasant Events Program (PEP), Information Support (IS)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Dementia, Agitation
A Music-Based Mobile App for People Living With Alzheimer's Disease and Related Dementias (ADRD)
The purpose of this pilot is to develop a mobile application that detects physiological measures of individuals with Alzheimer's disease and related dementias and triggers auto-play of personalized songs in a wearable device.
- Conditions
- Dementia, Agitation, Depressive Symptoms
- Trial name
- NCT06140342
- Testing
- Feasibility study of music-based mobile app
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Autotune Me LLC
Depression, Major Depressive Disorder
Incorporating Stepped Care Approach Into e-CBT for Depression
This randomized trial intervention will provide e-CBT for MDD through the Online Psychotherapy Tool (OPTT), a secure, cloud-based, digital mental health platform.
- Conditions
- Depression, Major Depressive Disorder, Depressive Symptoms
- Trial name
- NCT04747873
- Testing
- e-CBT, Stepped Care
- Where
- Canada
- Volunteers
- 79 people
- Sponsor
- Dr. Nazanin Alavi
Depression
Electrical Stimulation in Patients With Unipolar Major Depression
Double Blinded Randomized Trial of eTNS as adjuvant treatment for Major Unipolar Depressive Disorder. The primary objective is to assess the safety and tolerability of eTNS (external trigeminal nerve stimulation) of the V1 branch…
- Trial name
- TREND2 (NCT02239822)
- Testing
- Stimulation of the trigeminal nerve (active stimulation)
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital do Coracao
Depressive Symptoms
Comparing Paroxetine and Duloxetine on Cardiovascular Measures
This double-blind placebo-controlled trial is designed to test and to compare the cardiovascular profile of paroxetine controlled release (CR) with duloxetine in outpatients with depressive symptoms.
- Trial name
- NCT00136383
- Testing
- paroxetine versus duloxetine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Anorexia Nervosa
Metreleptin in Anorexia Nervosa
The treatment of anorexia nervosa often proves to be difficult. There are no drugs that work specifically for the treatment of anorexia nervosa.
- Trial name
- METRAN (NCT06305182)
- Testing
- Metreleptin, Sodium chloride
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Gabriella Milos
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.